


Claims

1. A compound of the Formula I



I

- 5 wherein

Q_a is phenyl or heteroaryl, and Q_a may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, trifluoromethyl, cyano, amino, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and (1-6C)alkoxycarbonyl;

R₁ and R₂ are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and

- 10 (2-6C)alkynyl; and

Q_b is phenyl, heteroaryl or heterocyclyl, and Q_b may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphanyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and

- 20 (3-6C)cycloalkylsulphonyl;

and wherein any of the substituents on Q_a or Q_b defined hereinbefore which comprise a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group one or more substituents selected from hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and

- 25 di-[(1-6C)alkyl]amino;

or a pharmaceutically-acceptable salt thereof.

2. A compound of the Formula I according to Claim 1 wherein

Q_a is phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, and Q_a may optionally bear 1 or 2 substituents selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy;

R₁ and R₂ are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and

5 (2-6C)alkynyl; and

Q_b is phenyl, heteroaryl or heterocyclyl, and Q_b may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,

(3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy,

(3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

10 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino,

di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-

(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl,

di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl,

(1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl,

15 N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the substituents on Q_a or Q_b defined hereinbefore which comprise a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group one or more substituents selected from hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and

20 di-[(1-6C)alkyl]amino;

or a pharmaceutically-acceptable salt thereof.

3. A compound of the Formula I according to Claim 1 or Claim 2 wherein

Q_a is phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, and Q_a may optionally bear 1 or 2

25 substituents selected from hydroxy, halogeno, (1-6C)alkyl and (1-6C)alkoxy; or a pharmaceutically-acceptable salt thereof.

4. A compound of the Formula I according to Claim 1 or Claim 2 wherein

Q_b is phenyl or heteroaryl, and Q_b may optionally bear 1 or 2 substituents selected from

30 hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,

(3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy,

(3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,

N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl,
 5 (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the substituents on Q_b which comprise a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group one or more substituents selected from hydroxy, cyano,
 10 amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino; or a pharmaceutically-acceptable salt thereof.

5. A compound of the Formula I according to Claim 1 or Claim 2 wherein Q_b is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thiadiazolyl, imidazolyl,
 15 isoxazolyl, oxazolyl, furanyl, thienyl, benzimidazolyl, isoquinolinyl, quinolinyl, benzothiazolyl or pyrido[1,2-a]imidazolyl, and Q_b may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl,
 20 N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl,
 25 N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;
 and wherein any of the substituents on Q_b which comprise a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group one or more substituents selected from hydroxy, cyano, amino,
 (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino; or a
 30 pharmaceutically-acceptable salt thereof.

6. A compound of the Formula I according to Claim 1 or Claim 2 wherein

R₁ and R₂ are each independently selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl; or a pharmaceutically-acceptable salt thereof.

7. A compound of the Formula I according to Claim 1 or Claim 2 wherein R₁ and R₂ are each independently selected from hydrogen and (1-6C)alkyl; or a pharmaceutically-acceptable salt thereof.

8. A compound of the Formula I according to Claim 1 wherein Q_a is phenyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, and Q_a may optionally bear 1 or 2 substituents selected from halogeno, (1-6C)alkyl and (1-6C)alkoxy; R₁ and R₂ are each independently selected from hydrogen and (1-6C)alkyl; and Q_b is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, thiadiazolyl, imidazolyl, isoxazolyl, oxazolyl, furanyl, thienyl, benzimidazolyl, isoquinolinyl, quinolinyl, benzothiazolyl or pyrido[1,2-a]imidazolyl, and Q_b may optionally bear 1 or 2 substituents selected from hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl; and wherein any of the substituents on Q_b which comprise a CH₂ group which is attached to 2 carbon atoms or a CH₃ group which is attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group one or more substituents selected from hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino; or a pharmaceutically-acceptable salt thereof.

9. A compound of the Formula I according to Claim 1 or Claim 2 selected from:-
3- {[4-(benzyloxy)benzoyl]amino} - N-cyclopropyl-4-methylbenzamide;
3- {[3-(benzyloxy)benzoyl]amino} - N-cyclopropyl-4-methylbenzamide;

- 4-(benzyloxy)-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methylbenzamide;
 4-(benzyloxy)-3-fluoro-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl} benzamide;
 4-(benzyloxy)-3-chloro-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl} benzamide;
N-cyclopropyl-4-methyl-3-{[4-(pyridin-2-ylmethoxy)benzoyl]amino} benzamide;
 5 N-cyclopropyl-4-methyl-3-{[4-(1,3-thiazol-4-ylmethoxy)benzoyl]amino} benzamide;
N-cyclopropyl-4-methyl-3-{[4-(pyridin-3-ylmethoxy)benzoyl]amino} benzamide;
N-cyclopropyl-4-methyl-3-({4-[(5-methylisoxazol-3-yl)methoxy]benzoyl} amino)benzamide;
 3-({4-[(5-chloro-1,2,3-thiadiazol-4-yl)methoxy]benzoyl} amino)-N-cyclopropyl-4-methylbenzamide;
 10 N-cyclopropyl-3-{[4-(imidazo[1,2-a]pyridin-2-ylmethoxy)benzoyl]amino}-4-methylbenzamide;
N-cyclopropyl-4-methyl-3-({4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzoyl} amino)benzamide;
N-cyclopropyl-3-({4-[(3,5-dimethylisoxazol-4-yl)methoxy]benzoyl} amino)-4-methylbenzamide;
 15 N-cyclopropyl-4-methyl-3-{[4-(1,2,5-thiadiazol-3-ylmethoxy)benzoyl]amino} benzamide;
 methyl 5-({4-[(5-[(cyclopropylamino)carbonyl]-2-methylphenyl} amino)carbonyl]phenoxy} methyl)-2-furoate;
 3-({4-[(2-chloro-1,3-thiazol-5-yl)methoxy]benzoyl} amino)-N-cyclopropyl-4-methylbenzamide;
 20 4-(benzyloxy)-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxybenzamide;
N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(pyridin-2-ylmethoxy)benzamide;
N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(1,3-thiazol-4-ylmethoxy)benzamide;
 25 N-cyclopropyl-4-methyl-3-{[3-methyl-4-(pyridin-2-ylmethoxy)benzoyl]amino} benzamide;
N-cyclopropyl-4-methyl-3-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)benzoyl]amino} benzamide;
N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide;
 30 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzamide;

- N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -4-[(3,5-dimethylisoxazol-4-yl) methoxy]-3-fluorobenzamide;
- N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -3-fluoro-4-(1,2,5-thiadiazol-3-ylmethoxy)benzamide;
- 5 N-cyclopropyl-4-methyl-3- {[3-(1,3-thiazol-4-ylmethoxy)benzoyl]amino} benzamide;
- N-cyclopropyl-4-methyl-3-({3-[(2-methyl-1,3-thiazol-4-yl) methoxy]benzoyl} amino)benzamide;
- N-cyclopropyl-4-methyl-3- {[3-(pyridin-2-ylmethoxy)benzoyl]amino} benzamide;
- N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -3-fluoro-4-(1,3-thiazol-4-ylmethoxy)benzamide;
- 10 N-cyclopropyl-4-methyl-3-({3-methyl-4-[(2-methyl-1,3-thiazol-4-yl) methoxy]benzoyl} amino)benzamide;
- N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -4-[(3,5-dimethylisoxazol-4-yl) methoxy]-3-methylbenzamide;
- 15 N-cyclopropyl-4-methyl-3- {[3-methyl-4-(1,2,5-thiadiazol-3-ylmethoxy)benzoyl]amino} benzamide;
- methyl 5-(({4-[({5-[(cyclopropylamino)carbonyl]-2-methylphenyl} amino)carbonyl]-2-methylphenoxy} methyl)-2-furoate;
- 3-chloro-N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -4-(pyridin-2-ylmethoxy)benzamide;
- 20 3-chloro-N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -4-(1,3-thiazol-4-ylmethoxy)benzamide;
- N-cyclopropyl-3-({3-[(3,5-dimethylisoxazol-4-yl) methoxy]benzoyl} amino)-4-methylbenzamide;
- 25 N-cyclopropyl-4-methyl-3- {[3-(1,2,5-thiadiazol-3-ylmethoxy)benzoyl]amino} benzamide;
- 3-({3-[(2-chloro-1,3-thiazol-5-yl) methoxy]benzoyl} amino)-N-cyclopropyl-4-methylbenzamide;
- N- {5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -3-fluoro-4-(imidazo[1,2-a]pyridin-2-ylmethoxy)benzamide;
- 30 N-cyclopropyl-3-({4-[(4-methoxypyridin-2-yl) methoxy]benzoyl} amino)-4-methylbenzamide;
- N-cyclopropyl-4-methyl-3- {[4-(1-pyridin-2-ylethoxy)benzoyl]amino} benzamide;
- N-cyclopropyl-3-({3-[(4-methoxypyridin-2-yl) methoxy]benzoyl} amino)-4-methylbenzamide;

N-cyclopropyl-3-[(4-{[5-(hydroxymethyl)pyridin-2-yl]methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3-[(4-{[5-(1-hydroxy-1-methylethyl)pyridin-2-yl]methoxy} benzoyl)amino]-4-methylbenzamide;

5 N-cyclopropyl-3-{[4-({5-[(isopropylamino)methyl]pyridin-2-yl} methoxy)benzoyl]amino}-4-methylbenzamide;

N-cyclopropyl-3-{[4-({5-[(dimethylamino)methyl]pyridin-2-yl} methoxy)benzoyl]amino}-4-methylbenzamide;

methyl 6-({4-[(5-[(cyclopropylamino)carbonyl]-2-

10 methylphenyl} amino)carbonyl]phenoxy} methyl)nicotinate;

N-cyclopropyl-3-{[4-({5-[2-(dimethylamino)ethoxy]pyridin-2-yl} methoxy)benzoyl]amino}-4-methylbenzamide;

N-cyclopropyl-3-[(4-{[5-(1,3-dioxolan-2-ylmethoxy)pyridin-2-yl]methoxy} benzoyl)amino]-4-methylbenzamide;

15 N-cyclopropyl-3-({4-[(5-hydroxypyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide
methyl 6-({4-[(5-[(cyclopropylamino)carbonyl]-2-

methylphenyl} amino)carbonyl]phenoxy} methyl)pyridine-2-carboxylate;

N-cyclopropyl-3-[(4-{[6-(hydroxymethyl)pyridin-2-yl]methoxy} benzoyl)amino]-4-methylbenzamide;

20 N-cyclopropyl-3-[(4-{[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]methoxy} benzoyl)amino]-4-methylbenzamide;

N-cyclopropyl-3-({4-[(6-{[2-(diethylamino)ethoxy]methyl} pyridin-2-yl)methoxy]benzoyl} amino)-4-methylbenzamide;

N-cyclopropyl-3-({4-[(6-{[2-(dimethylamino)ethoxy]methyl} pyridin-2-

25 yl)methoxy]benzoyl} amino)-4-methylbenzamide;

N-cyclopropyl-4-methyl-3-({4-[(1-oxidopyridin-2-yl)methoxy]benzoyl} amino)benzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(imidazo[1,2-a]pyridin-2-ylmethoxy)pyrimidine-5-carboxamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(1,3-thiazol-2-ylmethoxy)pyrimidine-

30 5-carboxamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(pyrimidin-2-ylmethoxy)pyrimidine-5-carboxamide;

- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-[(1-methyl-1H-imidazol-2-yl)methoxy]pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-[(1,5-dimethyl-1H-pyrazol-3-yl)methoxy]pyrimidine-5-carboxamide;
- 5 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-[(1,3-dimethyl-1H-pyrazol-5-yl)methoxy]pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-[(3-methylpyridin-2-yl)methoxy]pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-[(1-methyl-1H-benzimidazol-2-yl)methoxy]pyrimidine-5-carboxamide;
- 10 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(isoquinolin-1-ylmethoxy)pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(quinolin-2-ylmethoxy)pyrimidine-5-carboxamide;
- 15 2-(1,3-benzothiazol-2-ylmethoxy)-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(1-pyridin-2-ylethoxy)pyrimidine-5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(1,3-thiazol-4-ylmethoxy)pyrimidine-
- 20 5-carboxamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(pyridin-2-ylmethoxy)pyrimidine-5-carboxamide;
- N-cyclopropyl-3-({4-[(5-cyclopropyl-1,3,4-thiadiazol-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;
- 25 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-6-(pyridin-2-ylmethoxy)nicotinamide;
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-5-(pyridin-2-ylmethoxy)pyrazine-2-carboxamide;
- 3-({4-[(6-bromopyridin-2-yl)methoxy]benzoyl} amino)-N-cyclopropyl-4-methylbenzamide
- N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3,5-difluoro-4-(pyridin-2-
- 30 ylmethoxy)benzamide;
- N-cyclopropyl-4-methyl-3-({4-[(6-methylpyridin-2-yl)methoxy]benzoyl} amino)benzamide;
- N-cyclopropyl-4-methyl-3-({4-[(3-methylpyridin-2-yl)methoxy]benzoyl} amino)benzamide;
- N-cyclopropyl-4-methyl-3-{[4-(pyrimidin-2-ylmethoxy)benzoyl]amino} benzamide;

N-cyclopropyl-4-methyl-3-{[4-(pyridazin-3-ylmethoxy)benzoyl]amino} benzamide;

N-cyclopropyl-3-{[4-(6-[(2-methoxyethyl)amino]pyridin-2-yl) methoxy]benzoyl]amino}-4-methylbenzamide;

N-cyclopropyl-3-({4-[(6-[[2-(dimethylamino)ethyl]amino}pyridin-2-

5 yl)methoxy]benzoyl} amino)-4-methylbenzamide;

5-(benzyloxy)-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl} pyridine-2-carboxamide


N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-5-(pyridin-2-ylmethoxy)pyridine-2-carboxamide; and

N-cyclopropyl-4-methyl-3-[(4-{[4-(methylsulfonyl)benzyl]oxy} benzoyl)amino]benzamide;

10 or a pharmaceutically-acceptable salt thereof.


10. A process for preparing a compound of the Formula I, or pharmaceutically-acceptable salt thereof which comprises:-

(a) reacting a benzoic acid of the Formula II, or a activated derivative thereof,



15


with an amine of the Formula III




under standard amide bond forming conditions, wherein Qa, Qb, R1 and R2 are as defined in Claim 1 or Claim 2 and wherein any functional group is optionally protected , and:

20

- (i) removing any protecting groups; and
 - (ii) optionally forming a pharmaceutically-acceptable salt;
- (b) reacting an acid of the Formula IV, or an activated derivative thereof,



with an aniline of the Formula VI



VI

under standard amide bond forming, wherein Q_a , Q_b , R_1 and R_2 are as defined in Claim 1 or Claim 2 and wherein any functional group is optionally protected, and:

- (i) removing any protecting groups;
- 5 (ii) optionally forming a pharmaceutically-acceptable salt;
- (c) for the preparation of a compound of the Formula I wherein a substituent on Q_a or Q_b is (1-6C)alkoxy or substituted (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino or substituted (1-6C)alkylamino, the alkylation of an amide derivative of the Formula I wherein a substituent on Q_a or Q_b is hydroxy or amino.

10

11. A pharmaceutical composition for use in the treatment of diseases mediated by cytokines which comprises compound of the Formula I as claimed in any one of claims 1 to 9, or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

15

12. A compound of the Formula I claimed in any one of claims 1 to 9, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy.

20 13. A compound of the Formula I claimed in any one of claims 1 to 9, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament.

14. A compound of the Formula I claimed in any one of claims 1 to 9, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the
25 treatment of medical conditions mediated by cytokines.

15. The use of a compound of the Formula I claimed in any one of claims 1 to 9, or a pharmaceutically-acceptable thereof, in the manufacture of a medicament for use in the

- 84 -

treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, AIDS, septic shock, congestive heart failure, ischaemic heart disease or psoriasis.